nature research

Corresponding author(s):	Hai-Hui Xue, Weiqun Peng
Last updated by author(s):	Aug 9, 2021

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section

_					
7.	۲a	ŤΙ	ΙST	т	\sim

n/a	Confirmed
	$oxed{x}$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	🗴 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	🕱 A description of all covariates tested
	🕱 A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	\blacksquare Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

Sequencing is performed on Hi-Seq2000 of Illumina in single end read mode with read length of 50 bp (RNAseq), or in paired end read mode with read length of 150 nucleotides (ChIPseq, DNase-seq, and Hi-C). Flow cytometry data were collected on FACSVerse cytometer.

Data analysis

For nextgen sequencing data, the following was used: Juicer(v1.21.01), hiclib(v0.8.0 https://github.com/mirnylab/hiclib-legacy), Picard(http://broadinstitute.github.io/picard/), bowtie2(v2.2.5.), FastQC (v0.11.4), MACS2(v2.1.1), SICER(v1.1), edgeR(v.3.20.7.2), HOMER(v4.11), Cuffdiff (v2.2.1), Tophat(v2.1.0), GSEA(v4.1.0).

For HiC_hub analysis, please refer the algorithm at https://github.com/lux563624348/HiC_Hubs. Details were listed in the method section. Flow cytometry data were analyzed on FlowJo v10.2 (TreeStar) and statistical analysis performed on Prism v8.0 (GraphPad).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The data reported in this paper are tabulated in the Supplementary Materials and archived on the GEO database under accession number GSE164713.

_							100	•	
Ηı		l-sp	$\Delta \alpha$	~ I † I	$r\Delta$	nc	١rt	ın	σ
	ı	IJK	\mathcal{I}	ا ا ا ب		ν	יו נ	111	۶
									$\mathbf{-}$

Please select the or	ne below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
x Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of t	he document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf
Life scier	nces study design
All studies must dis	close on these points even when the disclosure is negative.
Sample size	No sample size was predetermined through calculation. All multiomics data were collected from at least two independent experiments, in
	two-four replicates, which are sufficient to provide statistical power in nextgen sequencing data analysis.
Data exclusions	No data were excluded from analyses.
Replication	For all experiments, at least two biological replicates were analyzed in at least two independent experiments. All the replicates showed
	consistent reproducibility or distinct clusters in nextgen sequencing analyses.
Randomization	Mice are randomly selected from a pool of 6-12 weeks mice for phenotypic analysis or sorting for Hi-C or multiomics analyses.
Blinding	The investigators were not blinded to the group allocation during data collection or analysis. Blinding is not relevant for analysis of nextgen
	sequencing data.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems	Methods		
n/a Involved in the study	n/a Involved in the study		
Antibodies	ChIP-seq		
Eukaryotic cell lines	Flow cytometry		
Palaeontology and archaeology	MRI-based neuroimaging		
Animals and other organisms	•		
Human research participants			
Clinical data			
Dual use research of concern			

Antibodies

Antibodies used Antibodies used in this studies were listed in Method.

Validation

In house made rabbit anti-Tcf1 sera were validated by immunoblotting and immunoprecipitation (supporting data in Fig. S2a-S2c).

The other antibodies are either validated by the manufacturers or in previous reports.

Animals and other organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Laboratory animals

Laboratory animals used in this study are described in the methods section.

Wild animals

No wild animals were used in this study.

Field-collected samples

Study did not involve samples collected in the field.

Ethics oversight

All experiments are performed under the protocol approved by the Institutional Animal Use and Care Committees of the University of lowa and Center for Discovery and Innovation, Hackensack University Medical Center.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

ChIP-seq

Data deposition

Confirm that both raw and final processed data have been deposited in a public database such as GEO.

Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links

May remain private before publication.

Go to https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE164713 Enter token ijynsamollijfgr into the box

Files in database submission

GSM5016615 naive CD8 T cells, Tcf1 ChIPseq GSM5016616 Tcf1-deficient CD8 T cells, Tcf1 ChIPseq GSM5017016 WT naïve CD8, DNase seq, rep1 GSM5017017 WT naïve CD8, DNase seq, rep2 GSM5017018 WT naïve CD8, DNase seq, rep3

GSM5017019 Tcf1/Lef1-deficient naïve CD8, DNase seq, rep1 GSM5017020 Tcf1/Lef1-deficient naïve CD8, DNase seq, rep2 GSM5017661 WT naïve CD8+ HiC Rep1

GSM5017662 WT naïve CD8+, HiC, Rep2 GSM5017663 Tcf1/Lef1-deficient naive CD8+, HiC, rep1

GSM5017663 TCT1/Lef1-deficient naive CD8+, HIC, rep1 GSM5017664 Tcf1/Lef1-deficient naive CD8+, HiC, rep2 GSM5017665 WT naive CD8+, H3K27ac ChIP-Seq, rep1

GSM5017666 WT naive CD8+ input

GSM5017667 WT naive CD8+, H3K27ac ChIP-Seq, rep2 GSM5017668 WT naive CD8+, H3K27ac ChIP-Seq, rep3 GSM5017669 WT naive CD8+, H3K27ac ChIP-Seq, rep4

GSM5017670 Tcf1/Lef1-deficient naive CD8+, H3K27ac ChIP-Seq, rep1

GSM5017671 Tcf1/Lef1-deficient naive CD8+ input

GSM5017672 Tcf1/Lef1-deficient naive CD8+, H3K27ac ChIP-Seq, rep2 GSM5017673 Tcf1/Lef1-deficient naive CD8+, H3K27ac ChIP-Seq, rep3

GSM5017674 WT CD8 RNAseq rep1 GSM5017675 WT CD8 RNAseq rep2 GSM5017676 WT CD8 RNAseq rep3

GSM5017677 Tcf1/Lef1-deficient CD8 RNAseq rep1 GSM5017678 Tcf1/Lef1-deficient CD8 RNAseq rep2 GSM5017679 Tcf1/Lef1-deficient CD8 RNAseq rep3

Genome browser session

(e.g. UCSC)

https://genome.ucsc.edu/s/lux563624348/CD8%2DHP

Methodology

Replicates

One replicate is provided for Tcf1 ChIPseq. Three to four replicates are provided for H3K27ac ChIP-seq.

Sequencing depth

Tcf1 ChIPseq:

length of reads: 151 bps

paired-end

WT_na: raw reads, 54,855,805; unique reads: 33,543,448. TKO_na: raw reads, 44,400,316; unique reads: 26,832,220.

H3K27ac:

length of reads: 151 bps

single-end:

WT_na: raw reads: 19,440,808, unique reads: 11,713709 dKO_na: raw reads: 26,762,606, unique reads: 12,235742

paired-end:

WT_na: raw reads: 33,397,929/44,728,983/42,672,064 unique reads: 27,494,246/34,958,043/34,733,452

dKO_na: raw reads: 32,837,708/31,664,726 unique reads: 25,716,725/ 28,642,749

Antibodies

Anti-Tcf1 antisera were made in-house by immunization of rabbits with full length Tcf1 recombinant protein. Anti-H3K27ac was purchased from Abcam (cat#: ab4729).

Peak calling parameters

Tcf1 peak calling by MACS2(v2.1.1): FDR < 0.05 , p<10(-5), Fold Enrichment >=4.

H3K27AC peak calling by SICER (v1.1): FDR < 0.01, windows size = 200bps and gap size = 400bps

Data quality

A total of 19,042 high confidence Tcf1 binding peaks were identified. For H3K27ac, a total of 65,563 and 82,213 H3K27ac peaks were identified in the pooled H3K27ac libraries for WT and dKO CD8+ T cells, respectively.

Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- | All plots are contour plots with outliers or pseudocolor plots.
- 🗶 A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation	Mouse spleens and lymph nodes were collected, and single cell suspension was made following standard procedures.
Instrument	FACSAria (BD Biosciences) for cell sorting, and FACSVerse (BD Biosciences) for analysis.
Software	FACSDiva (BD Biosciences) software was used for data collection. FlowJo v10.2 was used for data analysis.
Cell population abundance	≥95% on sorted cells, which was determined by flow cytometry analysis on post-sorted cells.
Gating strategy	Live lymphocytes were gated the known location through FSC-A/SSC-A. Doublets were removed by using FSC-A/FSC-W. CD4 and CD8 T cells cells were gated on TCRb+ cells.

x Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.